Enveric Biosciences已正式启动其先导神经塑形剂候选药物EB-003的研究性新药(IND)申报所需的关键基因毒性研究。这项进展标志着该候选药物在向临床开发阶段迈进的过程中,迈出了重要的监管准备步伐。
Enveric Biosciences已正式启动其先导神经塑形剂候选药物EB-003的研究性新药(IND)申报所需的关键基因毒性研究。这项进展标志着该候选药物在向临床开发阶段迈进的过程中,迈出了重要的监管准备步伐。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.